|Mr. Robert G. Finizio||Co-Founder, CEO & Director||1.37M||7.5M||1971|
|Mr. John C. K. Milligan IV||Pres, Sec. & Director||869.21k||10.54M||1962|
|Mr. Daniel Alan Cartwright||CFO & Treasurer||721.48k||346.4k||1958|
|Mr. Mitchell L. Krassan||Exec. VP and Chief Strategy & Performance Officer||605.36k||N/A||1966|
|Mr. Michael Donegan||VP of Fin.||395.25k||N/A||1968|
TherapeuticsMD, Inc. operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. In addition, it commercializes IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
TherapeuticsMD, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 2; Compensation: 8.